Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Recommendation of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has received an average rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $42.8889.

Several analysts recently issued reports on the stock. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st.

Insider Activity

In related news, EVP Eliyahu Kalif sold 106,563 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the completion of the sale, the executive vice president directly owned 65,621 shares in the company, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $25,000. Cornerstone Planning Group LLC grew its position in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the period. Allworth Financial LP grew its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. EverSource Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC increased its stake in Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.7%

Shares of TEVA opened at $36.36 on Friday. The stock has a 50 day moving average price of $34.64 and a 200 day moving average price of $33.28. Teva Pharmaceutical Industries has a one year low of $18.21 and a one year high of $38.37. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The stock has a market capitalization of $42.37 billion, a price-to-earnings ratio of 60.60, a PEG ratio of 4.57 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.14 billion for the quarter. Equities research analysts forecast that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current fiscal year.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.